Vedanta Biosciences announced on 11/6/18 preclinical data for VE800, the Company’s orally-administered, live biotherapeutic product candidate in immuno-oncology. The study showed that VE800 elicited an anti-tumor immune response as a monotherapy and also enhanced effects of immune checkpoint inhibitors.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,